The immune system in the normal endometrium and implications for endometrial cancer development

Journal of Reproductive Immunology

Volumn 109, Issue , 2015, Pages 7-16

  Vanderstraeten, A ^a   Tuyaerts, S ^a   Amant, F ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Endometrial cancer; Endometrium; Immune system; Immunotherapy

Indexed keywords

DEFENSIN; ESTROGEN; HLA DR ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 15; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAT3 PROTEIN;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIABETES MELLITUS; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE; MEMORY T LYMPHOCYTE; MENSTRUAL CYCLE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NEUTROPHIL; OBESITY; OVARY CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; ENDOMETRIUM TUMOR; IMMUNOLOGY; PATHOLOGY;

ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS;

EID: 84928770109     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2014.12.006     Document Type: Review

References (73)

1. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I. Endometrial cancer. Lancet 2005, 366:491-505.
2. Ambros R.A., Kurman R.J. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 1992, 69:1424-1431.
3. Arruvito L., Sanz M., Banham A.H., Fainboim L. Expansion of CD4+ CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J. Immunol. 2007, 178:2572-2578.
4. Austin H., Austin J.M., Partridge E.E., Hatch K.D., Shingleton H.M. Endometrial cancer, obesity, and body fat distribution. Cancer Res. 1991, 51:568-572.
5. Barrier B.F., Kendall B.S., Sharpe-Timms K.L., Kost E.R. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol. Oncol. 2006, 103:25-30.
6. Bijen C.B., Bantema-Joppe E.J., de Jong R.A., Leffers N., Mourits M.J., Eggink H.F., Van der Zee A.G., Hollema H., De Bock G.H., Nijman H.W. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int. J. Cancer 2010, 126:1417-1427.
7. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
8. Brunner A., Hinterholzer S., Riss P., Heinze G., Brustmann H. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol. Oncol. 2012, 124:105-111.
9. Chang W.C., Li C.H., Huang S.C., Chang D.Y., Chou L.Y., Sheu B.C. Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma. Cancer 2010, 116:5777-5788.
10. Contassot E., Preynat-Seauve O., French L., Huard B. Lymph node tumor metastases: more susceptible than primary tumors to CD8(+) T-cell immune destruction. Trends Immunol. 2009, 30:569-573.
11. Dandona P., Aljada A., Ghanim H., Mohanty P., Tripathy C., Hofmeyer D., Chaudhuri A. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J. Clin. Endocrinol. Metab. 2004, 89:5043-5047.
12. de Jong R.A., Leffers N., Boezen H.M., Ten Hoor K.A., Van der Zee A.G., Hollema H., Nijman H.W. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol. Oncol. 2009, 114:105-110.
13. de Jong R.A., Kema I.P., Boerma A., Boezen H.M., Van der Want J.J., Gooden M.J., Hollema H., Nijman H.W. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol. Oncol. 2012, 126:474-480.
14. Deligdisch L. Morphologic correlates of host response in endometrial carcinoma. Am. J. Reprod. Immunol. 1982, 2:54-57.
15. El-Hamarneh T., Hey-Cunningham A.J., Berbic M., Al-Jefout M., Fraser I.S., Black K. Cellular immune environment in endometrial polyps. Fertil. Steril. 2013, 100:1364-1372.
16. Elinav E., Nowarski R., Thaiss C.A., Hu B., Jin C., Flavell R.A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13:759-771.
17. Fahey J.V., Wira C.R. Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. J. Infect. Dis. 2002, 185:1606-1613.
18. Fahey J.V., Schaefer T.M., Wira C.R. Sex hormone modulation of human uterine epithelial cell immune responses. Integr. Comp. Biol. 2006, 46:1082-1087.
19. Fahey J.V., Wallace P.K., Johnson K., Guyre P.M., Wira C.R. Antigen presentation by human uterine epithelial cells to autologous T cells. Am. J. Reprod. Immunol. 2006, 55:1-11.
20. Fattorossi A., Battaglia A., Ferrandina G., Buzzonetti A., Legge F., Salutari V., Scambia G. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol. Oncol. 2004, 92:106-115.
21. Ferguson A., Moore M., Fox H. Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumour cells and infiltrating leucocytes. Br. J. Cancer 1985, 52:551-563.
22. Friedenreich C.M., Langley A.R., Speidel T.P., Lau D.C., Courneya K.S., Csizmadi I., Magliocco A.M., Yasui Y., Cook L.S. Case-control study of inflammatory markers and the risk of endometrial cancer. Eur. J. Cancer Prev. 2013, 22:374-379.
23. Garzetti G.G., Ciavattini A., Goteri G., Tranquilli A.L., Muzzioli M., Fabris N., De Nictolis M., Romanini C. Natural killer cell activity in stage I endometrial carcinoma: correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol. Oncol. 1994, 55:111-114.
24. Garzetti G.G., Ciavattini A., Goteri G., Romanini C. Nodal immune reactivity in FIGO (International Federation of Gyn-Ob) Stage I endometrial carcinoma: relationship with myometrial invasion. Acta Obstet. Gynecol. Scand. 1995, 74:723-728.
25. Giatromanolaki A., Bates G.J., Koukourakis M.I., Sivridis E., Gatter K.C., Harris A.L., Banham A.H. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol. Oncol. 2008, 110:216-221.
26. Goc J., Fridman W.H., Sautes-Fridman C., Dieu-Nosjean M.C. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013, 2:e26836.
27. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
28. Hickey D.K., Patel M.V., Fahey J.V., Wira C.R. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J. Reprod. Immunol. 2011, 88:185-194.
29. Ibrahim E.C., Guerra N., Lacombe M.J., Angevin E., Chouaib S., Carosella E.D., Caignard A., Paul P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 2001, 61:6838-6845.
30. Iclozan C., Antonia S., Chiappori A., Chen D.T., Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 2013, 62:909-918.
31. Ino K., Yamamoto E., Shibata K., Kajiyama H., Yoshida N., Terauchi M., Nawa A., Nagasaka T., Takikawa O., Kikkawa F. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin. Cancer Res. 2008, 14:2310-2317.
32. Jia J., Wang Z., Li X., Wang X., Wang X. Morphological characteristics and co-stimulatory molecule (CD80, CD86, CD40) expression in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012, 160:223-227.
33. Kondratiev S., Sabo E., Yakirevich E., Lavie O., Resnick M.B. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 2004, 10:4450-4456.
34. Lazaris A., Chatzigianni E.B., Xidias G., Panoskaltsis T.A., Thomopoulou G.C., Eftychiadis C.A., Michalas S., Patsouris E.S. Tissue evaluation of immune markers in endometrial and cervical carcinomas. J. Exp. Clin. Cancer Res. 2004, 23:269-275.
35. Lijun Z., Xin Z., Danhua S., Xiaoping L., Jianliu W., Huilan W., Lihui W. Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma. Int. J. Gynecol. Cancer 2012, 22:836-841.
36. Lobo S.C., Huang S.T., Germeyer A., Dosiou C., Vo K.C., Tulac S., Nayak N.R., Giudice L.C. The immune environment in human endometrium during the window of implantation. Am. J. Reprod. Immunol. 2004, 52:244-251.
37. Male V., Hughes T., Mcclory S., Colucci F., Caligiuri M.A., Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J. Immunol. 2010, 185:3913-3918.
38. Manaster I., Mizrahi S., Goldman-Wohl D., Sela H.Y., Stern-Ginossar N., Lankry D., Gruda R., Hurwitz A., Bdolah Y., Haimov-Kochman R., Yagel S., Mandelboim O. Endometrial NK cells are special immature cells that await pregnancy. J. Immunol. 2008, 181:1869-1876.
39. Marshall R.J., Jones D.B. An immunohistochemical study of lymphoid tissue in human endometrium. Int. J. Gynecol. Pathol. 1988, 7:225-235.
40. Miyatake T., Tringler B., Liu W., Liu S.H., Papkoff J., Enomoto T., Torkko K.C., Dehn D.L., Swisher A., Shroyer K.R. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol. Oncol. 2007, 106:119-127.
41. Modugno F., Ness R.B., Chen C., Weiss N.S. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol. Biomark. Prev. 2005, 14:2840-2847.
42. Nielsen J.S., Nelson B.H. Tumor-infiltrating B cells and T cells: working together to promote patient survival. Oncoimmunology 2012, 1:1623-1625.
43. Ochiel D.O., Ghosh M., Fahey J.V., Guyre P.M., Wira C.R. Human uterine epithelial cell secretions regulate dendritic cell differentiation and responses to TLR ligands. J. Leukoc. Biol. 2010, 88:435-444.
44. Ohno S., Ohno Y., Suzuki N., Kamei T., Koike K., Inagawa H., Kohchi C., Soma G., Inoue M. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004, 24:3335-3342.
45. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., Avril M.F., Dausset J., Guillet J.G., Carosella E.D. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4510-4515.
46. Pfister G., Savino W. Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective. Neuroimmunomodulation 2008, 15:351-364.
47. Potischman N., Hoover R.N., Brinton L.A., Siiteri P., Dorgan J.F., Swanson C.A., Berman M.L., Mortel R., Twiggs L.B., Barrett R.J., Wilbanks G.D., Persky V., Lurain J.R. Case-control study of endogenous steroid hormones and endometrial cancer. J. Natl. Cancer Inst. 1996, 88:1127-1135.
48. Qian Y., Shen L., Cheng L., Wu Z., Yao H. B7-H4 expression in various tumors determined using a novel developed monoclonal antibody. Clin. Exp. Med. 2011, 11:163-170.
49. Raber P.L., Thevenot P., Sierra R., Wyczechowska D., Halle D., Ramirez M.E., Ochoa A., Fletcher M., Velasco C., Wilk A., Reiss K., Rodriguez P.C. Subpopulations of myeloid-derived suppressor cells (MDSC) impair T cell responses through independent nitric oxide-related pathways. Int. J. Cancer 2014, 134:2853-2864.
50. Schulke L., Manconi F., Markham R., Fraser I.S. Endometrial dendritic cell populations during the normal menstrual cycle. Hum. Reprod. 2008, 23:1574-1580.
51. Silverberg S.G., Sasano N., Yajima A. Endometrial carcinoma in Miyagi Prefecture, Japan: histopathologic analysis of a cancer registry-based series and comparison with cases in American women. Cancer 1982, 49:1504-1510.
52. Soeda S., Nakamura N., Ozeki T., Nishiyama H., Hojo H., Yamada H., Abe M., Sato A. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol. Oncol. 2008, 109:122-128.
53. Tabibzadeh S.S., Satyaswaroop P.G. Sex steroid receptors in lymphoid cells of human endometrium. Am. J. Clin. Pathol. 1989, 91:656-663.
54. Tamiolakis D., Venizelos J., Lambropoulou M., Nikolaidou S., Tsikouras P., Jivannakis T., Papadopoulos N. Local immune response in serous papillary carcinoma of the endometrium. Histol. Histopathol. 2005, 20:403-408.
55. Timonen T., Lehtovirta P., Saksela E. Interleukin-2-stimulated natural killer activity against malignant and benign endometrium. Int. J. Cancer 1987, 40:479-483.
56. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., Mcdermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., Mcmiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., Mcdonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
57. Vanderstraeten A., Luyten C., Verbist G., Tuyaerts S., Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol. Immunother. 2014, 63:545-557.
58. Visser M., Bouter L.M., Mcquillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
59. Wallace P.K., Yeaman G.R., Johnson K., Collins J.E., Guyre P.M., Wira C.R. MHC class II expression and antigen presentation by human endometrial cells. J. Steroid Biochem. Mol. Biol. 2001, 76:203-211.
60. Wang T., Rohan T.E., Gunter M.J., Xue X., Wactawski-Wende J., Rajpathak S.N., Cushman M., Strickler H.D., Kaplan R.C., Wassertheil-Smoller S., Scherer P.E., Ho G.Y. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol. Biomark. Prev. 2011, 20:971-977.
61. White H.D., Crassi K.M., Givan A.L., Stern J.E., Gonzalez J.L., Memoli V.A., Green W.R., Wira C.R. CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J. Immunol. 1997, 158:3017-3027.
62. Wira C.R., Fahey J.V., Sentman C.L., Pioli P.A., Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol. Rev. 2005, 206:306-335.
63. Wira C.R., Grant-Tschudy K.S., Crane-Godreau M.A. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am. J. Reprod. Immunol. 2005, 53:65-76.
64. Wira C.R., Fahey J.V., Ghosh M., Patel M.V., Hickey D.K., Ochiel D.O. Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am. J. Reprod. Immunol. 2010, 63:544-565.
65. Witkiewicz A.K., Mcconnell T., Potoczek M., Emmons R.V., Kurman R.J. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Hum. Pathol. 2010, 41:26-32.
66. Yamagami W., Susumu N., Tanaka H., Hirasawa A., Banno K., Suzuki N., Tsuda H., Tsukazaki K., Aoki D. Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int. J. Gynecol. Cancer 2011, 21:1628-1634.
67. Yamamoto K., Masuko K., Takahashi S., Ikeda Y., Kato T., Mizushima Y., Hayashi K., Nishioka K. Accumulation of distinct T cell clonotypes in human solid tumors. J. Immunol. 1995, 154:1804-1809.
68. Yang D., Chertov O., Bykovskaia S.N., Chen Q., Buffo M.J., Shogan J., Anderson M., Schroder J.M., Wang J.M., Howard O.M., Oppenheim J.J. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528.
69. Yang Z., Kong B., Mosser D.M., Zhang X. TLRs, macrophages, and NK cells: our understandings of their functions in uterus and ovary. Int. Immunopharmacol. 2011, 11:1442-1450.
70. Yeaman G.R., Guyre P.M., Fanger M.W., Collins J.E., White H.D., Rathbun W., Orndorff K.A., Gonzalez J., Stern J.E., Wira C.R. Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J. Leukoc. Biol. 1997, 61:427-435.
71. Yeaman G.R., Collins J.E., Fanger M.W., Wira C.R., Lydyard P.M. CD8+ T cells in human uterine endometrial lymphoid aggregates: evidence for accumulation of cells by trafficking. Immunology 2001, 102:434-440.
72. Zeleniuch-Jacquotte A., Akhmedkhanov A., Kato I., Koenig K.L., Shore R.E., Kim M.Y., Levitz M., Mittal K.R., Raju U., Banerjee S., Toniolo P. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br. J. Cancer 2001, 84:975-981.
73. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.